MTG may exert particular therapeutic effects in patients with Alzheimer disease (AD) and Parkinson’s disease [PD; 42, 43] by protecting against neurotoxicity induced by beta-amyloid (Aβ) peptides [44, 45]. This evidence concerns the gene PRSS3 and early-onset autosomal dominant Alzheimer disease.